Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study

Oncology Group ◽

Oncology Group Study ◽

Ancillary Study ◽

Chemotherapy Administration

Delayed recurrences and survival after relapse in patients initially treated with intraperitoneal chemotherapy for advanced ovarian cancer: A Gynecologic Oncology Group study.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5577 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5577-5577

Author(s):

Daniel Stuart Kapp ◽

James Java ◽

Thomas J. Herzog ◽

Maurie Markman ◽

Deborah Kay Armstrong ◽

...

Keyword(s):

Ovarian Cancer ◽

Intraperitoneal Chemotherapy ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Survival After Relapse

Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study

Annals of Oncology ◽

10.1093/annonc/mdv500 ◽

2016 ◽

Vol 27 (1) ◽

pp. 114-121 ◽

Cited By ~ 45

Author(s):

K.S. Tewari ◽

J.J. Java ◽

R.N. Eskander ◽

B.J. Monk ◽

R.A. Burger

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Complete Resection ◽

Early Initiation ◽

Oncology Group ◽

Phase III Gynecologic Oncology Group Study of Advanced Ovarian Cancer: Bevacizumab Added to Initial Chemotherapy Extends Progression-Free Survival

Oncology Times ◽

10.1097/01.cot.0000387947.51553.29 ◽

2010 ◽

Vol 32 (Sup 1) ◽

pp. 17

Author(s):

&NA;

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Progression Free Survival ◽

Phase Iii ◽

Oncology Group ◽

Free Survival ◽

A Phase II Study of Fazarabine in Patients with Advanced Ovarian Cancer A Gynecologic Oncology Group Study

American Journal of Clinical Oncology ◽

10.1097/00000421-199504000-00012 ◽

1995 ◽

Vol 18 (2) ◽

pp. 156-157 ◽

Cited By ~ 10

Author(s):

Alberto Manetta ◽

John A. Blessing ◽

Katherine Y. Look

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Oncology Group ◽

Pilot Evaluation of High-Dose Carboplatin and Paclitaxel Followed by High-Dose Melphalan Supported by Peripheral Blood Stem Cells in Previously Untreated Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2003.6882 ◽

2003 ◽

Vol 88 (1) ◽

pp. 3-8 ◽

Cited By ~ 26

Author(s):

Russell J. Schilder ◽

Mark F. Brady ◽

David Spriggs ◽

Thomas Shea

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

High Dose ◽

Oncology Group ◽

Peripheral Blood Stem Cells ◽

Oncology Group Study ◽

Blood Stem Cells ◽

High Dose Melphalan

Phase III randomized trial of maintenance pegylated liposomal doxorubicin (PLD) / carboplatin versus without in patients with advanced ovarian cancer: An Asian Gynecologic Oncology Group study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5584 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5584-5584

Author(s):

Chyong-Huey Lai ◽

Elizabeth Vallikad ◽

Hao Lin ◽

Lan-Yan Yang ◽

Yu-Che Ou ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomized Trial ◽

Liposomal Doxorubicin ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Pegylated Liposomal Doxorubicin ◽

Phase Iii ◽

Oncology Group ◽

Secondary Cytoreductive Surgery at Second-Look Laparotomy in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.1997.4806 ◽

1997 ◽

Vol 66 (2) ◽

pp. 171-178 ◽

Cited By ~ 45

Author(s):

Laura Williams ◽

Virginia L. Brunetto ◽

Edgardo Yordan ◽

Philip J. DiSaia ◽

William T. Creasman

Keyword(s):

Ovarian Cancer ◽

Cytoreductive Surgery ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Secondary Cytoreductive Surgery ◽

Second Look

Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group

Journal of Gynecologic Oncology ◽

10.3802/jgo.2020.31.e5 ◽

2020 ◽

Vol 31 (1) ◽

Cited By ~ 1

Author(s):

Chyong-Huey Lai ◽

Elizabeth Vallikad ◽

Hao Lin ◽

Lan-Yan Yang ◽

Shih-Ming Jung ◽

...

Keyword(s):

Ovarian Cancer ◽

Liposomal Doxorubicin ◽

Gynecologic Oncology ◽

Randomized Study ◽

Advanced Ovarian Cancer ◽

Pegylated Liposomal Doxorubicin ◽

Oncology Group

Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2006.02.014 ◽

2006 ◽

Vol 101 (3) ◽

pp. 390-397 ◽

Cited By ~ 26

Author(s):

Angeles Alvarez Secord ◽

Paula S. Lee ◽

Kathleen M. Darcy ◽

Laura J. Havrilesky ◽

Lisa A. Grace ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Poor Prognosis ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Maspin Expression

Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)

BMC Cancer ◽

10.1186/s12885-019-5514-7 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 4

Author(s):

Young Shin Chung ◽

Sang-Yoon Park ◽

Jung-Yun Lee ◽

Jeong-Yeol Park ◽

Jeong-Won Lee ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Gynecologic Oncology ◽

Serous Carcinoma ◽

High Grade ◽

Advanced Stage ◽

Oncology Group ◽